Now Your Patient

Can Be Unstoppable

For 90 Days

Eversense is the only CGM system with a 90-day subcutaneous sensor – giving patients the longest wear time ever, along with unmatched convenience and accuracy.1,2,3

Forging New Paths in Diabetes Management

Now you can provide your patients with innovative CGM technology that can simplify their lives and provide better clinical outcomes. Eversense is the only CGM system with a 90‑day, subcutaneous sensor giving patients the longest wear time ever, along with unmatched convenience and accuracy.1,2


Up to 90-Days Sensor Wear

Vibe alert

Transmitter provides
on-body vibe alerts


Fully implantable sensor


4 sensor changes a year vs 26-52 for other CGM systems


Exceptional accuracy – especially in the 40-60 mg/dL range2


Up to 90-Days Sensor Wear


Transmitter provides
on-body vibe alerts


Fully implantable sensor


4 sensor changes a year vs 26-52 for other CGM systems


Exceptional accuracy – especially in the 40-60 mg/dL range2

Unmet Needs in CGM Technology Can Cause Patients to Struggle With Wear-time Goals

Patients with diabetes receive optimal clinical benefit from continuous glucose monitoring when the sensor is worn more than 80% of the time.4


There are many limitations that result in patients struggling to continue using traditional CGM technology.6

  • Accuracy issues
  • Frequent sensor changes
  • Uncomfortable to wear
  • Adhesive skin irritation
  • Too many false alarms 

As a result

Over 25% of users discontinue use within a year.7

Eversense delivers Unmatched wear time and improved glycemic outcomes

The advanced sensor technology and under-the-skin sensor help patients reach unprecedented levels of wear time, leading to improved clinical outcomes.

  • 98% wear time in clinical trials1,2



With 98% real time in clinical trials,1,2 Eversense exceeds the 80% wear-time for optimal clinical benefits.1,2,7


Eversense CGM


Required for optimal clinical benefit

Exceptional Accuracy

Highly Accurate Alert Detection Rates

Within a 10-minute window, the Eversense CGM System uses threshold and predictive alerts to detect:2

95% of hypoglycemic events (70 mg/dL)

99% of hyperglycemic events (180 mg/dL)



vibe alerts

In addition to visual and auditory alerts, Eversense’s unique on-body vibe alerts add an extra measure of confidence, especially when patients are sleeping, or when their mobile device is not close by.

Improved Clinical Outcomes

Multiple clinical trials have demonstrated that Eversense CGM use can reduce A1c levels.1


How We Outpace Other CGMS


Up to 90-day sensor life

4 sensor changes per year

Only 4 ‘Day 1' warm-up periods

Sensor insertion by HCP

Transmitter is removable and provides unique on-body vibe alerts

Sensor stays put no matter what

Reduced irritation with gentle, silicone-based adhesive7

Traditional CGMs

Short sensor life of 7-14 days

26-52 sensor changes per year

26 - 52 ‘Day 1’ warm-up periods

Need to self-insert the sensor

Transmitter must remain adhered to skin for sensor duration

Percutaneous sensor can be dislodged during everyday activities

Acrylate-based adhesives can cause skin irritation

Ready to Get Started as a Provider?

Ready to prescribe Eversense CGM? Just fill out a simple form with a few details and we will contact you to answer questions and get you started.


  1. Christiansen MP, Klaff LJ, Brazg R, et al. A Prospective Multicenter Evaluation of the Accuracy of a Novel Implanted Continuous Glucose Sensor: PRECISE II. Diabetes Technology & Therapeutics. 2018;20(3):197-206. doi:10.1089/dia.2017.0142.
  2. Christiansen MP, Klaff LJ, Bailey TS, Brazg R, Carlson G, Tweden KS. A Prospective Multicenter Evaluation of the Accuracy and Safety of an Implanted Continuous Glucose Sensor: The PRECISION Study. Diabetes Technology & Therapeutics. 2019;21(5):231-237. doi:10.1089/dia.2019.0020.
  3. Barnard KD, Kropff J, et al. Acceptability of Implantable Continuous Glucose Monitoring Sensor: Journal of Diabetes Science and Technology 2018, Vol. 12(3) 634 -638. DOI: 10.1177.
  4. Slattery D, Choudhary P. Clinical Use of Continuous Glucose Monitoring in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics 2017; 19, Supplement 2. DOI:10.1089.dia.2017.0051
  5. Engler R, Routh TL, Lucisano JY. Adoption Barriers for Continuous Glucose Monitoring and Their Potential Reduction With a Fully Implanted System: Results From Patient Preference Surveys. Clinical Diabetes. 2018;36(1):50-58. doi:10.2337/cd17-0053.
  6. Shengsheng Yu, Biju Varughese, et. al. Healthcare Resource Waste Associated with Patient Nonadherence and Early Discontinuation of Traditional Continuous Glucose Monitoring in Real-World Settings: A Multicountry Analysis: Diabetes Technol Ther. 2018 Jun 1; 20(6): 420-427
  7. Sanchez P, Ghosh-Dastidar S, Tweden K, Kaufman F. Real-World Data from the First US Commercial Users of an Implantable Continuous Glucose Sensor. Diabetes Technol Ther. Published online August 12, 2019, DOI:10.1089/dia.2019.0234